Carthera
Denver, United States
Michael Canney PhD is the Chief Scientific Officer of Carthera. Carthera is developing the SonoCloud®, an intracranial ultrasound implant that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. The SonoCloud-9 device is currently being tested in multiple clinical trials in patients with glioblastoma in France and the United States.